证券日报网讯 8月19日晚间，泰林生物发布公告称，公司于2025年4月24日召开第四届董事会第七次会 议、第四届监事会第七次会议，于2025年5月19日召开2024年年度股东大会，审议通过了《关于2021年 向不特定对象发行可转换公司债券募集资金投资项目结项并将节余募集资金投入新项目及永久补充流动 资金的议案》。基于前述事项，公司2021年向不特定对象发行可转换公司债券募集资金专户"细胞治疗 产业化装备制造基地项目"中存放的募集资金及相关利息收入已支取完毕，且募集资金专户无后续使用 用途，为便于公司管理，公司已于近日完成上述募集资金专用账户的销户手续。 （编辑 任世碧） ...

证券代码：300813 证券简称：泰林生物 公告编号：2025-059 浙江泰林生物技术股份有限公司 关于部分募集资金专用账户销户完成的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、募集资金基本情况 三、本次注销的部分募集资金专户情况 公司于 2025 年 4 月 24 日召开第四届董事会第七次会议、第四届监事会第七 次会议，于 2025 年 5 月 19 日召开 2024 年年度股东大会，审议通过了《关于 2021 年向不特定对象发行可转换公司债券募集资金投资项目结项并将节余募集资金 投入新项目及永久补充流动资金的议案》，具体内容详见公司在巨潮资讯网 （http://www.cninfo.com.cn）披露的《关于 2021 年向不特定对象发行可转换 公司债券募集资金投资项目结项并将节余募集资金投入新项目及永久补充流动 资金的公告》（公告编号：2025-030）。 基于前述事项，公司 2021 年向不特定对象发行可转换公司债券募集资金专 户"细胞治疗产业化装备制造基地项目"（专户账号：3301040160019344418） 中存放的募集资金及相 ...

资金流向方面，8月15日主力资金净流出270.93万元，近五个交易日累计净流出1592.86万元。 截至2025年8月15日15时，泰林生物股价报23.74元，较前一交易日下跌0.05元，跌幅0.21%。当日开盘 价为23.72元，最高触及24.14元，最低下探23.64元，成交量为19829手，成交额0.47亿元。 泰林生物主营业务为医疗器械及生命科学领域的技术研发与产品生产，涉及机器人概念、空间站概念等 板块。公司产品主要应用于生物制药、医疗卫生等领域。 消息面上，泰林生物全资子公司浙江泰林新材料有限公司近日取得《不动产权证书》，涉及相关资产确 权。 风险提示：股市有风险，投资需谨慎。 ...

Group 1 - The core point of the article is that Tailin Biological (300813) announced that its wholly-owned subsidiary, Zhejiang Tailin New Materials Co., Ltd., has recently obtained the "Real Estate Property Certificate" [1]

证券代码：300813 证券简称：泰林生物 公告编号：2025-058 浙江泰林生物技术股份有限公司 关于全资子公司取得不动产权证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、对外投资概述 浙江泰林生物技术股份有限公司（以下简称"公司"）于 2025 年 4 月 24 日召开第四届董事会第七次会议、第四届监事会第七次会议，于 2025 年 5 月 19 日召开 2024 年年度股东大会，审议通过了《关于 2021 年向不特定对象发行可转 换公司债券募集资金投资项目结项并将节余募集资金投入新项目及永久补充流 动资金的议案》《关于拟与杭州富春湾新城管理委员会签订高性能过滤器及配套 功 能 膜 产 业 化 项 目 合 同 书 的 议 案 》， 具 体 内 容 详 见 公 司 在 巨 潮 资 讯 网 （http://www.cninfo.com.cn）披露的《关于 2021 年向不特定对象发行可转换 公司债券募集资金投资项目结项并将节余募集资金投入新项目及永久补充流动 资金的公告》（公告编号：2025-030）、《关于拟与杭州富春湾新城管理委员会签 订 ...

Core Viewpoint - The article discusses the approval and details of the Guangdong Province Synthetic Biology Manufacturing Pilot Platform Project, highlighting its investment, construction scale, and the upcoming SynBioCon 2025 conference focused on synthetic biology and green manufacturing trends [3][4][5]. Project Approval and Details - The Guangdong Provincial Development and Reform Commission approved the preliminary design budget for the Synthetic Biology Manufacturing Pilot Platform Project, with a total investment of 21,733,000 yuan, including engineering costs of 19,459,000 yuan and other expenses [3]. - The project will establish four major pilot platforms: an intelligent microbial pilot platform, a functional macromolecule pilot platform, a green biomass methanol pilot platform, and an intelligent plant pilot platform, covering a construction area of approximately 8,500 square meters and acquiring about 365 sets of instruments and equipment [3][4]. SynBioCon 2025 Conference - The SynBioCon 2025 conference will be held from August 20 to 22 in Ningbo, Zhejiang, focusing on four main areas: AI in biological manufacturing, green chemical engineering and new materials, future food, and future agriculture [5]. - The conference aims to explore the development trends of the biological manufacturing industry during the 14th Five-Year Plan, innovations driven by AI, and the continuous vitality brought by new technologies and products [5]. - Various activities will take place during the conference, including a youth forum, high-level discussions, and a closed-door seminar on the "2025 Blue Book for AI Empowering Biological Manufacturing Industry Innovation" [5][11].

Group 1 - The core viewpoint of the news highlights a significant rise in virus prevention stocks, particularly in response to the reported cases of Chikungunya fever in Foshan, Guangdong Province [1][2][3] - Notable stock performances include Zhifei Biological, which increased by 16.86%, and Watson Bio, which rose by 13.39%, among others [2] - The total market capitalization of Zhifei Biological is reported at 57.7 billion, while Watson Bio stands at 21 billion [2] Group 2 - As of July 22, Foshan has reported a total of 3,195 confirmed cases of Chikungunya fever, primarily concentrated in the Shunde District [2] - The World Health Organization has issued a warning regarding mosquito-borne diseases, urging countries to prepare for potential outbreaks [3]

Company Overview - Zhejiang Tailin Biological Technology Co., Ltd. specializes in microbial testing and pollution control, innovative drug research and production, process analysis, and protective measures in the life sciences sector [2] - The company provides high-quality products and solutions for industries such as biomedicine, healthcare, food and beverage, and environmental protection [2] Financial Performance - For Q1 2025, the company reported revenue of 66.94 million yuan, a year-on-year decrease of 16.33% [2] - The net profit for the same period was 3.53 million yuan, down 39.93% year-on-year, with a sales gross margin of 49.27% [2] Market Position - As of July 22, the company's stock closed at 22.8 yuan, with a rolling price-to-earnings (PE) ratio of 258.12, marking a new low in 163 days [1] - The average PE ratio in the medical device industry is 53.47, with a median of 37.00, placing Tailin Biological at the 117th position in the industry ranking [1][3] Shareholding Structure - As of Q1 2025, there is one institutional holder of Tailin Biological, which is a fund holding 511,200 shares valued at 1.1 million yuan [1]

Group 1 - Yaxin Security plans to reduce its shareholding by up to 3%, totaling no more than 12 million shares, from August 8, 2025, to November 7, 2025 [1] - Shangwei Co. intends to issue up to 180 million shares to its controlling shareholder, raising no more than 1.144 billion yuan for digital upgrades and working capital [1][2] - Anker Innovations is exploring the possibility of overseas share issuance to enhance its global strategy and brand image, with no specific plan confirmed yet [3] Group 2 - AVIC Xi'an Aircraft Industry Group's chairman resigned due to work changes, effective immediately upon submission of the resignation [4] - Tianci Materials signed a procurement cooperation agreement to supply at least 550,000 tons of electrolyte products to Chuangneng New Energy from 2025 to 2030, enhancing market share and profitability [5][6] - Guangshentang's innovative drug GST-HG131 has been included in the list of breakthrough therapies, but this does not guarantee market approval or immediate financial impact [7][8] Group 3 - Chaozhuo Aerospace plans to reduce its shareholding by up to 3%, totaling no more than 896,000 shares, from August 7, 2025, to November 6, 2025 [9] - Taiji Group intends to repurchase shares worth between 80 million and 120 million yuan, with a maximum price of 28.03 yuan per share, to be used for cancellation [11][12] - Xibu Materials plans to invest 125 million yuan in a private placement by its subsidiary to raise 147 million yuan for working capital and loan repayment [13] Group 4 - Shantui Co. plans to issue H-shares and apply for listing on the Hong Kong Stock Exchange [14] - *ST Huawang intends to acquire 55.5% of Niwei Power for 666 million yuan, entering the new energy hybrid vehicle sector [15] - Tailin Bio's controlling shareholder plans to reduce its shareholding by up to 1.5%, totaling no more than 1.8195 million shares, for personal funding needs [17] Group 5 - Huicheng Vacuum plans to reduce its shareholding by up to 3%, totaling no more than 3 million shares, from August 7, 2025, to November 6, 2025 [18][19] - Kesi Co.'s actual controller plans to reduce its shareholding by up to 3%, totaling no more than 14.27 million shares, for personal funding needs [20][21] - Zhongchong Co.'s controlling shareholder plans to reduce its shareholding by up to 1.5%, totaling no more than 4.56 million shares, for funding needs [22][23] Group 6 - Shanhigh Environmental plans to raise no more than 718 million yuan through a private placement to supplement working capital and repay bank loans [24][25] - Zhongrong Electric plans to invest 114 million yuan in the construction of the Sinok New Energy Technology Park, expected to be completed by the end of 2027 [26] - Kaisen New Materials' shareholder plans to transfer 4.75% of its shares, totaling 20 million shares, for personal funding needs [27] Group 7 - Xinxin Standard's controlling shareholder plans to reduce its shareholding by up to 3%, totaling no more than 6.7792 million shares, for personal funding needs [28] - Chuhuan Technology plans to invest 9.99 million yuan in a partnership focused on high-end manufacturing, including semiconductors and new materials [29] - Shankai Intelligent's stock will resume trading after a share transfer agreement with Changjiang Aerospace, which will become the controlling shareholder [30]

智通财经7月16日电，泰林生物(300813.SZ)公告称，持股5%以上股东暨控股股东、实际控制人的一致行 动人高得投资计划通过集中竞价、大宗交易或两者相结合等方式，于本减持计划公告之日起15个交易日 后的3个月内减持公司股份不超过1,819,517股，占公司总股本的1.50%。减持价格将根据减持时的股票 市场价格确定。 泰林生物：股东高得投资拟减持不超过1.5%公司股份 ...